EXTENDED REPORT

Better efficacy of methotrexate given by intramuscular injection than orally in patients with rheumatoid arthritis

J Wegrzyn¹, P Adeleine², P Miossec¹

¹ Departments of Immunology and Rheumatology, Hôpital Edouard Herriot, Lyon, France
² Departments of Epidemiology and Medical Information, Hospices Civils de Lyon

Correspondence to:
Correspondence to:
Pr P Miossec
Clinical Immunology Unit, Departments of Immunology and Rheumatology, Hôpital Edouard Herriot, Lyon, 69 437 Lyon Cedex 03, France; miossec{at}univ-lyon1.fr

Objective: To compare the clinical efficacy of methotrexate and tolerance to the drug in patients with rheumatoid arthritis who were switched from intramuscular to oral administration because of a shortage of the intramuscular preparation.

Methods: 143 patients were switched from intramuscular to oral methotrexate. Of these, 47 were switched back to the intramuscular form. A multiple choice questionnaire was sent by mail to evaluate clinical and biological criteria of efficacy and tolerance.

Results: When methotrexate was first switched from intramuscular to oral administration, increased disease activity, exacerbation of morning pain and hand stiffness, duration of morning stiffness, increased joint pain, and increased joint swelling were observed. There was a greater frequency of gastrointestinal symptoms, but without a significant increase in liver abnormalities. When intramuscular methotrexate became available again, 47 of the 143 patients were switched back and were followed for at least three months. On average, disease manifestations were improved and side effects reduced by the switch.

Conclusions: Methotrexate given intramuscularly had improved clinical efficacy with fewer side effects than given orally. Intramuscular methotrexate administration should be considered when rheumatoid arthritis remains active in spite of high dose oral methotrexate.

Keywords: rheumatoid arthritis; methotrexate; intramuscular administration

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

• Hernandez-Rodriguez, J., Cid, M. C., Lopez-Soto, A., Espigol-Frigole, G., Bosch, X. (2009). Treatment of Polymyalgia Rheumatica: A Systematic Review. Arch Intern Med 169: 1839-1850 [Abstract] [Full Text]  
• Visser, K, Katchamart, W, Loza, E, Martinez-Lopez, J A, Salliot, C, Trudeau, J, Bombardier, C, Carmona, L, van der Heijde, D, Bijlsma, J W J, Boumpas, D T, Canhao, H, Edwards, C J, Hamuryudan, V, Kvien, T K, Leeb, B F, Martin-Mola, E M, Mielants, H, Muller-Ladner, U, Murphy, G, Ostergaard, M, Pereira, I A, Ramos-Remus, C, Valentini, G, Zochling, J, Dougados, M (2009). Multinational evidence-based recommendations for the use of methotrexate in rheumatic disorders with a focus on rheumatoid arthritis: integrating systematic literature research and expert opinion of a broad international panel of rheumatologists in the 3E Initiative. Ann Rheum Dis 68: 1086-1093 [Abstract] [Full Text]  
• Visser, K, van der Heijde, D (2009). Optimal dosage and route of administration of methotrexate in rheumatoid arthritis: a systematic review of the literature. Ann Rheum Dis 68: 1094-1099 [Abstract] [Full Text]  
• Bharadwaj, A., Agrawal, S., Batley, M., Hammond, A. (2008). Use of parenteral methotrexate significantly reduces the need for biological therapy. Rheumatology (Oxford) 47: 222-222 [Full Text]